Ono Pharmaceutical
Ono Pharmaceutical Co., Ltd., commonly referred to as Ono Pharma, is a prominent player in the biopharmaceutical industry, headquartered in Osaka, Japan. Founded in 1717, the company has a rich history of innovation, focusing on the research, development, and commercialisation of novel therapeutics, particularly in oncology, immunology, and pain management. Ono Pharma is renowned for its flagship product, Opdivo (nivolumab), a groundbreaking immunotherapy that has transformed cancer treatment paradigms. The company’s commitment to advancing healthcare is reflected in its robust pipeline and strategic partnerships, positioning it as a leader in the global pharmaceutical market. With a strong presence in Japan and expanding operations in North America and Europe, Ono Pharmaceutical continues to make significant strides in delivering unique and effective solutions for patients worldwide.
DitchCarbon Score
How does Ono Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ono Pharmaceutical's score of 67 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ono Pharmaceutical's reported carbon emissions
In 2023, Ono Pharmaceutical reported total greenhouse gas emissions of approximately 36,700,000 kg CO2e. This includes 6,700,000 kg CO2e from Scope 1, 9,400,000 kg CO2e from Scope 2, and a significant 23,600,000 kg CO2e from Scope 3 emissions. Notably, the Scope 3 emissions are primarily driven by capital goods, which account for about 18,400,000 kg CO2e. Ono Pharmaceutical has set ambitious climate commitments, aiming to achieve carbon neutrality for its Scope 1 and 2 emissions by 2025. Additionally, the company has committed to reducing its absolute Scope 1 and 2 emissions by 55% by FY2030, with a long-term goal of reaching zero greenhouse gas emissions by FY2035. For Scope 3 emissions, Ono aims for a 30% reduction by FY2030 and a 60% reduction by FY2050, using FY2017 as the baseline year. These targets align with industry standards for climate action, reflecting Ono's commitment to sustainability and its proactive approach to mitigating climate change impacts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | 0,000,000 | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | 00,000,000 | - | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 3 | - | - | - | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ono Pharmaceutical is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
